Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ado-trastuzumab emtansine

View Patient Information
An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.
Synonym:ado trastuzumab emtansine
trastuzumab emtansine
trastuzumab-DM1
trastuzumab-MCC-DM1
trastuzumab-MCC-DM1 antibody-drug conjugate
trastuzumab-MCC-DM1 immunoconjugate
US brand name:Kadcyla
Abbreviation:T-DM1
Code name:PRO132365
RO5304020
Chemical structure:immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal RhuMab HER2 gamma1-chain), disulfide with human-mouse monoclonal RhuMab HER2 light chain, dimer, tetraamide with N2'-(3-((1-((4-carboxycyclohexyl)methyl)-2,5-dioxo-3-pyrrolidinyl)thio)-1-oxopropyl)-N2'-deacetylMaytansine
Search NCI's Drug Dictionary